Dicerna Ready To Challenge Alnylam’s RNAi Dominance In 2020
Alliances Help Fund Pivotal Studies
Alnylam set for further expansion in ‘gene silencing’ but Dicerna could have best-in-class rival.
You may also be interested in...
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.
The resignation of David Horn Solomon last month was a setback for Silence but the company believes it will benefit from the growing prominence given to RNAi technology.
Givosiran was approved by the US FDA for the treatment of acute hepatic porphyria, a rare generic blood disorder, nearly three months ahead of the action date.